Patents by Inventor Hans-Henning BÖHM

Hans-Henning BÖHM has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PHARMACEUTICAL COMBINATION OF ANTI CEACAM6 AND TIM3 ANTIBODIES
    Publication number: 20220089721
    Abstract: The present disclosure relates to combinations of at least two components, component A and component B, component A being anti-CEACAM6 antibody TPP-3310 and component B being an anti-TIM-3 antibody, preferentially cobolimab, MBG-453, BMS-986258, Sym-023, LY-3321367 or INCAGN-2390.
    Type: Application
    Filed: December 12, 2019
    Publication date: March 24, 2022
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Jrög WILLUDA, Mark TRAUTWEIN, Rienk OFFRINGA, Hans-Henning BÖHM, Philipp BECKHOVE
  • PHARMACEUTICAL COMBINATION OF ANTI-CEACAM6 AND EITHER ANTI-PD-1 OR ANTI-PD-L1 ANTIBODIES FOR THE TREATMENT OF CANCER
    Publication number: 20220010017
    Abstract: Pharmaceutical Combination for the Treatment of Cancer The present invention relates to combinations of at least two components, component A and component B for use in the treatment of cancer, component A being an anti-CEACAM6 antibody and component B being an anti-PD-1 antibody, preferentially nivolumab, or pembrolizumab, or an anti-PD-L1 antibody, preferentially atezolizumab, avelumab, or durvalumab.
    Type: Application
    Filed: November 7, 2019
    Publication date: January 13, 2022
    Applicants: Bayer Aktiengesellschaft, Deutsches Krebsforschungszentrum
    Inventors: Jörg WILLUDA, Mark TRAUTWEIN, Rienk OFFRINGA, Philipp BECKHOVE, Hans-Henning BÖHM